Berotralstat is an oral medication approved for the prophylactic treatment of hereditary angioedema (HAE) in adult patients [1][2]. It is a targeted therapy designed to reduce the frequency of HAE attacks [1].
What is Hereditary Angioedema (HAE)?
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling (angioedema) in various parts of the body, including the limbs, abdomen, face, and airway [3]. These attacks can be painful and potentially life-threatening if they affect the airway [3]. HAE is caused by genetic mutations that lead to overproduction of bradykinin, a substance that causes swelling [4].
How Does Berotralstat Work?
Berotralstat functions as a plasma kallikrein inhibitor [1]. Plasma kallikrein is an enzyme that plays a key role in the overproduction of bradykinin in individuals with HAE [4]. By inhibiting this enzyme, berotralstat aims to prevent the cascade that leads to swelling attacks [1][4].
When Did Berotralstat Get Approved?
Berotralstat received U.S. Food and Drug Administration (FDA) approval on December 16, 2020 [1][2].
What Are the Potential Side Effects of Berotralstat?
Common side effects reported with berotralstat include gastrointestinal issues such as diarrhea, nausea, abdominal pain, and vomiting [1]. Some patients may also experience headache or fatigue [1].
How Does Berotralstat Compare to Other HAE Treatments?
Unlike some other HAE treatments that are administered via injection or infusion, berotralstat is taken orally, offering a different administration route for patients [1]. Other HAE treatments may target different pathways or be used for acute attack management rather than prophylaxis [3].
What is the Expected Lifespan of Berotralstat's Market Exclusivity?
The patent landscape for berotralstat is complex and subject to ongoing developments. Information on specific patent expiry dates and any associated litigation can be found through resources like DrugPatentWatch.com [5]. These patents are crucial for determining the duration of market exclusivity for the drug.